07 Feb 2024: Samsung Biologics and LegoChem Sign ADC Partnership Agreement
Samsung Biologics, a global CDMO, has signed an agreement with LegoChem Biosciences, a biotech company specializing in ADC programs
The partnership involves Samsung Biologics providing antibody development and drug substance manufacturing services for LegoChem’s ADC program targeting solid tumors
LegoChem aims to submit an Investigational New Drug application to the FDA by the first half of 2025, with promising non-clinical efficacy data
The collaboration seeks to develop efficient and safe therapeutics, with Samsung Biologics leveraging its expertise in ADC development and manufacturing to support LegoChem’s innovative pipeline